Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(1 year, 3 months from now) | |
US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(5 years from now) | |
US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(5 years from now) | |
US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(5 years from now) | |
US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(7 years from now) | |
US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(7 years from now) |
Zurampic is owned by Ironwood Pharms Inc.
Zurampic contains Lesinurad.
Zurampic has a total of 9 drug patents out of which 0 drug patents have expired.
Zurampic was authorised for market use on 22 December, 2015.
Zurampic is available in tablet;oral dosage forms.
Zurampic can be used as coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; below 6mg/dl in patients having uric acid deposits; and/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%, treatment of gout, reduction of serum uric acid levels, treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone, treatment of hyperuricemia.
Drug patent challenges can be filed against Zurampic from 23 December, 2019.
The generics of Zurampic are possible to be released after 29 February, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of gout; Treatment of hyperuricemia; ...
Dosage: TABLET;ORAL